Soft Tissue Sarcoma Trial Results
Imatinib (Gleevec®) Reduces Cancer Recurrence in Patients with Surgically Removed GIST
(Posted: 06/25/2007, Updated: 05/19/2009) - Patients with localized gastrointestinal stromal tumors (GIST) who took imatinib (Gleevec®) after surgical removal of the primary tumor were less likely to have a recurrence of their cancer, according to findings presented at the 2007 ASCO meeting in Chicago.
Imatinib 'Treatment Holiday' Risks Disease Progression
(Posted: 04/17/2007) - Patients whose advanced gastrointestinal stromal tumors (GIST) are controlled with the drug imatinib (Gleevec®) risk rapid progression of disease if treatment is interrupted, according to the March 20, 2007, Journal of Clinical Oncology.
Gleevec Decreases Cancer Recurrence for Patients with Primary Gastrointestinal Stromal Tumor
(Posted: 04/12/2007) - Preliminary results from a large, randomized, placebo-controlled clinical trial for patients with primary gastrointestinal stromal tumor, a type of tumor usually found in the stomach or small intestine, showed that patients who received imatinib mesylate (Gleevec ®) after complete removal of their tumor were significantly less likely to have a recurrence of their cancer compared to those who did not receive imatinib.
(Posted: 06/25/2007, Updated: 05/19/2009) - Patients with localized gastrointestinal stromal tumors (GIST) who took imatinib (Gleevec®) after surgical removal of the primary tumor were less likely to have a recurrence of their cancer, according to findings presented at the 2007 ASCO meeting in Chicago.
Imatinib 'Treatment Holiday' Risks Disease Progression
(Posted: 04/17/2007) - Patients whose advanced gastrointestinal stromal tumors (GIST) are controlled with the drug imatinib (Gleevec®) risk rapid progression of disease if treatment is interrupted, according to the March 20, 2007, Journal of Clinical Oncology.
Gleevec Decreases Cancer Recurrence for Patients with Primary Gastrointestinal Stromal Tumor
(Posted: 04/12/2007) - Preliminary results from a large, randomized, placebo-controlled clinical trial for patients with primary gastrointestinal stromal tumor, a type of tumor usually found in the stomach or small intestine, showed that patients who received imatinib mesylate (Gleevec ®) after complete removal of their tumor were significantly less likely to have a recurrence of their cancer compared to those who did not receive imatinib.
